The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome Type 2 diabetes obesity or prediabetes and the metabolic sequale of these diseases including cardiovascular cerebrovascular renal and hepatic diseases comprising the step of: administering to a patient suffering from the metabolic syndrome Type 2 diabetes obesity or prediabetes a pharmaceutical composition comprising (1 ) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject.
